Abstract
The case of a young woman of 19-years-old is presented; whom the diagnosis was made of a left parietal-occipital xanthoastrocytoma pleomorphic anaplastic; this neoplasia is rare and usually affects the pediatric and young adult population. This generally debuts with seizures and their pathognomonic histologic characteristics are the pleomorphic cells with cytoplasmatic lipid vacuolation and the reactivity of glial fibrillary acidic protein (GFAP) and S100. The study of new markers that may provide other therapeutic opportunities has allowed finding mutations in the BRAF oncogene. This tumor has a more aggressive anaplastic variant that is treated with surgery and chemoradation. In our case after several progressions to other interventions, we used bevacizumab and carmustine as second-line treatment obtaining complete response.
References
Kepes JJ, Rubinstein LJ, Eng LF. Pleomorphic xanthoastrocytoma: A distinctive meningocerebral glioma of young subjects with relatively favorable prognosis A study of 12 cases. Cancer. 1979;44(5):1839-52.
Yu TM, Liubinas SY, Gonzales M, Drummond KJ. Malignant potential of pleomorphic xanthoastrocytoma. J Clin Neurosci. 2012;19(1):12-20.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20.
Giannini C, Scheithauer BW, Burger PC, Brat DJ, Wollan PC, Lach B, et al. Pleomorphic xanthoastrocytoma. What do we really know about it? Cancer. 1999;85(9):2033-45.
Tan T-C, Ho L-C, Yu C-P, Cheung F-C. Pleomorphic xantho-astrocytoma: report of two cases and review of the prognostic factors. J Clin Neurosci. 2004;11(2):203-7.
Hirose T, Ishizawa K, Sugiyama K, Kageji T, Ueki K, Kannuki S. Pleomorphic xanthoastrocytoma: a comparative pathological study between conventional and anaplastic types. Histopathology. 2008;52(2):183-93.
Schmidt Y, Kleinschmidt-DeMasters BK, Aisner D, Lillehei K, Damek D. Anaplastic PXA in adults: case series with clinicopathologic and molecular features. J Neurooncol. 2013;111(1):59-69.
Giannini CMD, Scheithauer BWMD, Lopes MBSMD, Hirose TMD, Kros JMMD, YandenBerg SRMD. Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol. 2002;26(4):479-85.
Nasuha NA, Daud AH, Ghazali MM, Yusoff AAM, Zainuddin N, Abdullah JM, et al. Molecular genetic analysis of anaplastic pleomorphic xanthoastrocytoma. Asian J Surg. 2003;26(2):120-5.
Douis H, Andronikou S, von Bezing H. Pleomorphic xanthoastrocytoma: Case series "with radiologic-pathological correlation and review of the literature. Eur J Radiol. 2008;68(1):5-8.
Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF Y600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397-405.
Marton E, Feletti A, Orvieto E, Longatti P. Malignant progression in pleomorphic xanthoastrocytoma: Personal experience and review of the literature. J Neurol Sci. 2007;252(2):144-53.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med. 2005;352(10):987-96.
Chamberlain M. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol. 2013;114(2):237-40.
Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Ker-loëguen Y, Cloughesy TF. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep. 2013;13(5):347.
Rao AAN, Laack NN, Giannini C, Wetmore C. Pleomorphic xanthoastrocytoma in children and adolescents. Pediatr. Blood Cancer. 2010;55(2):290-4.
Katayama K, Asano K, Shimamura N, Ogasawara Y, Naraoka M, Ohkuma H, et al. A case of pleomorphic xanthoastrocytoma with anaplastic features in the pineal gland. Brain Tumor Pathol. 2013;30(4):242-6.
Marucci G, Morandi L. Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma. J Neurooncol. 2011;105(2):397-400.
Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LY, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943-53.
Wick W Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954-63.
Rojas L, Cardona AF, Wills B, Arrieta O, Yargas CA, Carranza H, et al. Profiling response to carmustine/bevacizumab in recurrent glioblastoma. J Clin Oncol. 2016;34(Supl. 15):2059.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.